Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01334294 · ClinicalTrials.gov registry record
Home Vision Monitoring Using the ForeseeHome Device Following Treatment of Neovascular Age Related Macular Degeneration
A clinical trial, sponsored by Notal Vision.
- Completed
- Registry status
- 120
- Enrollment target
NCT01334294 is a clinical trial that has completed, run by Notal Vision. The registered enrollment target is 120 participants.
The verdict
NCT01334294 has completed, sponsored by Notal Vision.
- COMPLETED
- Registry status
- 120 participants
- Enrollment target
Study Summary
ForeseeHome, an FDA-approved home device, was specifically designed for unsupervised Preferential-Hyperacuity-Perimeter (PHP) testing of Age Related Macular Degeneration (AMD) patients at home by characterizing central and paracentral metamorphopsia . The purpose of the current study is to evaluate if, in post-treatment patients, PHP parameters as measured with the ForeseeHome are in agreement with clinical decisions and retinal characteristics as measured with optical coherence tomography (OCT).
Interventions
- DEVICE ForeseeHome
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2011-04 |
| Est. Completion | 2014-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01334294
The ClinicalTrials.gov registry entry for NCT01334294 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Notal Vision, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ForeseeHome is the first listed.
NCT01334294 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01334294 about?
NCT01334294 is a clinical study titled "Home Vision Monitoring Using the ForeseeHome Device Following Treatment of Neovascular Age Related Macular Degeneration". ForeseeHome, an FDA-approved home device, was specifically designed for unsupervised Preferential-Hyperacuity-Perimeter (PHP) testing of Age Related Macular Degeneration (AMD) patients at home by characterizing central and paracentral metamorphopsia . The purpose of the current study is to evaluate ...
What is the current status of trial NCT01334294?
This trial is currently completed. The enrollment target is 120 participants. The study started on 2011-04. Estimated completion is 2014-03.
What interventions are being tested in trial NCT01334294?
The interventions under investigation include: ForeseeHome (DEVICE).
Who is sponsoring clinical trial NCT01334294?
This trial is sponsored by Notal Vision, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.